ArticleAmerican journal of translational research2026
Clinical effect of obinutuzumab in the treatment of idiopathic membranous nephropathy.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to evaluate the clinical efficacy and safety of obinutuzumab (OBZ) in patients with Idiopathic membranous nephropathy (IMN), comparing outcomes between treatment-naïve and previously treated individuals.
methodsThis was a single-center, retrospective cohort study involving 163 adult IMN patients who received at least one cycle of OBZ between January 2020 and December 2023. Participants were stratified into an Initial Therapy group (first-line OBZ, n=51) and a Non-Initial Therapy group (prior immunosuppressive treatment failure, n=112). Key data assessed at baseline, 1, 3, 6, and 12 months included: 24-hour urinary protein excretion (UPE), serum albumin, estimated glomerular filtration rate (eGFR), serum anti-phospholipase A2 receptor antibody (anti-PLA2R) titer, peripheral B-cell counts, and treatment-related adverse events.
resultsAmong 163 enrolled patients, clinical remission rates at 3 months were significantly higher in the Initial Therapy group (54.90% vs. 37.50%,
conclusionOBZ is an effective and well-tolerated treatment for IMN, with an earlier initiation associated with faster clinical and serological response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.